FdaApplication
NDA 021417
Identifiers
- fda_app_no: NDA021417
Properties
| Property | Value |
|---|---|
| applicant_name | WYETH PHARMS INC |
| application_type | NDA |
Revenue by product
PREMARIN
| Period | Revenue |
|---|---|
| Q3 2024 | $90.0M |
| Q2 2024 | $108.0M |
| Q4 2023 | $98.0M |
| Q3 2023 | $92.0M |
| Q2 2023 | $95.0M |
| Q1 2023 | $112.0M |
| Q4 2022 | $128.0M |
| Q3 2022 | $110.0M |
| Q2 2022 | $115.0M |
| Q1 2022 | $102.0M |
| Q4 2021 | $143.0M |
| Q3 2021 | $148.0M |
| Q2 2021 | $128.0M |
| Q1 2021 | $143.0M |
| Q4 2020 | $209.0M |
| Q3 2020 | $168.0M |
| Q2 2020 | $152.0M |
| Q1 2020 | $152.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| PREMARIN | ESTROGENS, CONJUGATED | 0.45MG | TABLET;ORAL |
| PREMARIN | ESTROGENS, CONJUGATED | 0.3MG | TABLET;ORAL |
2 products